Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.
Melanoma News
Tilsotolimod Provides No Added Benefit in Advanced Melanoma
The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.
Tilsotolimod Provides No Added Benefit in Advanced Melanoma
The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.
Gene Expression Profile Testing Offers Clinicians a Path to Safely Avoid SLNB in Low-Risk Melanoma Patients
New prospective data from the DECIDE study reinforce the role of the 31-GEP test in clinical decision-making.